Business, energy, technology, markets and global industry news from Business News Today

Influenza

PharmaDeviceNews Influenza
ArkBio’s completion of Phase I dosing for AK0406 moves the investigational long-acting influenza prophylaxis candidate into extended safety, pharmacokinetic and immunogenicity follow-up. Representative image.
Pharma & Biotech

What does ArkBio’s AK0406 dosing milestone mean for long-acting influenza prevention?

ArkBio has dosed all Phase I cohorts of AK0406, moving the long-acting influenza prophylaxis candidate into six-month safety follow-up.

Read More
A clinician performs a nasal swab beside a compact molecular testing system as AMDI’s sub-10-minute Fast PCR platform targets faster influenza, RSV and COVID-19 diagnosis in urgent-care settings. Representative image.
Medical Devices & Diagnostics

AMDI wins FDA clearance for ten-minute PCR, but can it disrupt point-of-care diagnostics?

Autonomous Medical Devices Incorporated has secured FDA clearance and a CLIA waiver for a four-virus PCR panel, but speed alone may not guarantee widespread adoption.

Read More
A healthcare professional administers a seasonal influenza vaccine to an older adult as Moderna’s MFLUSIVA moves closer to a potential United States approval. Representative image.
Pharma & Biotech

Is mRNA-1010 the breakthrough Moderna needs beyond COVID-19 vaccines?

Moderna’s mRNA-1010 has cleared a major regulatory hurdle, but evidence in older adults, higher reactogenicity and seasonal contracting could limit its early impact.

Read More
Representative image of pharmaceutical manufacturing and respiratory medicine research. Lupin Limited’s China approval for oseltamivir phosphate oral suspension highlights the continuing role of paediatric-friendly antiviral formulations in influenza treatment access.
Pharma & Biotech

Can Lupin use oseltamivir approval to deepen its China respiratory medicine strategy?

Lupin’s China approval adds a paediatric-friendly flu antiviral to its portfolio. See why formulation and access still matter in generics.

Read More
Pharma & Biotech

Lupin just cracked China with a flu drug. Why investors may want to look closer

Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.

Read More
Pharma & Biotech

ArkBio pushes AK0406 into first-in-human testing, but can a long-acting flu antiviral carve out real clinical space?

ArkBio has begun Phase I testing of AK0406 in Australia. Read why this long-acting influenza candidate matters and what risks still need proving.

Read More
Medical Devices & Diagnostics

Why FDA’s clearance of ACON’s Flowflex Plus test marks a turning point in home diagnostics

FDA clears Flowflex Plus 4-in-1 test for RSV, flu, and COVID in infants and adults. Find out what this means for diagnostics, families, and industry players.

Read More
Pharma & Biotech

Hyundai Bioscience begins U.S. Phase 2 trial of Xafty for COVID, flu, and RSV

Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.

Read More